Canaccord raised the firm’s price target on TransMedics (TMDX) to $152 from $148 and keeps a Buy rating on the shares. The firm said they delivered another good quarter with $160.8M versus $155.4M consensus, driven once again by US Liver, and augmented by strong guidance. Canaccord believes the focus will now shift towards European expansion and the all-important heart and lung clinical trials as potential drivers but not specifically quantified in 2026 guidance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- Balancing Strong Execution With Long-Term Catalysts: Why TransMedics Merits a Hold Rating
- Closing Bell Movers: First Solar down 12% on earnings miss
- TransMedics reports Q4 EPS $2.62 with items, consensus 37c
- TransMedics sees FY26 revenue $727M-$757M, consensus $725.04M
- Is TMDX a Buy, Before Earnings?